Market Players, Key Developments, and Competitive Intelligence To learn more about this report, Key Developments On June 30, 2025, Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on peptide-based therapeutics, announced the nomination of PN-477, a triple agonist peptide targeting GLP-1, GIP, and GCG receptors, for obesity treatment
This session will provide practical strategies for early diagnosis and risk assessment, using non-invasive diagnostic tools
On top of this, the endometrium also encompasses atrial and venous endothelial cells, contributing to endometrial angiogenesis [7, 8]
doi: 10.1210/clinem/dgad286 75 DubeyPRaymondGVMoserABKharkarSBezmanLMoserHW
Chances are that you have had instructions on their storage, but the following are common storage practices